ALS Centre Netherlands

UMC Utrecht

The ALS Centre Netherlands is the Dutch national centre of expertise on ALS.

Logo-UMC-Utrecht-2019_4
UMC Utrecht

We schedule all diagnostic research and consultations for each patient on one day. Around 90% of all Dutch ALS patients are diagnosed in our centre and over 500 patients are diagnosed each year. Prof. Leonard van den Berg, director of the ALS Centre Netherlands, is one of the initiators of the TRICALS platform with the aim to speed up the research for an ALS treatment by increasing collaboration between patients, industry and ALS centres. He is also one of the initiators of Project Mine (www.projectmine.com), which is the largest research effort worldwide to study the genetic basis of ALS. Additionally, our research focuses on epidemiology, brain imaging and cognitive functioning of ALS patients.

Contact
Location
Heidelberglaan 100, 3584 CX Utrecht, Nederland

Our team

Leonard van den Berg

Professor of Neurology and Chair of TRICALS

Leonard van den Berg is professor of neurology and chairman of TRICALS. […]

Leonard van den Berg
Current trials
Recruiting
Phase ii

DAZALS trial

Industry trial
In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS (also known as MND) to understand its safety (side effects) and to determine if dazucorilant can slow down the worsening of the disease. The effects of dazucorilant will be compared to the effects of a placebo. This study is sponsored by Corcept Therapeutics.
Read more
Active
Phase ii

CARDINALS

Industry trial
The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms. Researchers will also test the safety and tolerability of the study drug and how the body responds to it. The study drug is a liquid that is swallowed 2 times a day.
Read more
Recruiting
Phase iii

FUSION trial

Industry trial
In this study we investigate the safety and efficacy of the study drug ‘ION363’ for the treatment of ALS caused by mutations in the FUS gene. About 1% to 5% of ALS cases are caused by FUS mutations.
Read more
Active
Phase iii

PHOENIX trial

Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Read more
Completed
Phase iii

ADORE trial

Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Read more
Active
Phase iii

TUDCA-ALS

Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.
Read more